Deciphering Circadian Rhythm–Related Molecular Subtypes in Breast Cancer and Establishing a Prognostic Prediction Model
BioMed Research International · 2025
DOI: 10.1155/bmri/9664238 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2025. Verfasst von Yanzhen Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hos…. Hauptthemen laut MEDLINE: Breast Neoplasms, Circadian Rhythm. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Background
Recent evidence suggests that alterations in circadian rhythm genes may lead to circadian rhythm disruption (CRD), which is a key mechanism in the progression of breast cancer. Therefore, investigating the role of circadian rhythm genes in the prognosis of breast cancer holds significant clinical value. Materials and Methods: We utilized expression profile data from the Gene Expression Omnibus (GEO) database to identify cancer features closely associated with CRD in breast cancer. Then, we analyzed publicly available datasets (including GEO, TCGA, and METABRIC) to identify alterations in core circadian genes significantly associated with patient survival across breast cancer and constructed a circadian‐related gene signature (CGS) based on these prognostic cancer features.
Results
Circadian rhythm–related genes (CRGs) were selected to construct a risk gene signature associated with individual prognosis, which was validated in six independent cohorts and demonstrated good predictive ability. We identified three circadian rhythm–associated subtypes with distinct prognoses, which exhibited significant differences in immune checkpoint molecules, drug sensitivity, and molecular features. Additionally, the gene signature and clinicopathologic features were integrated to develop a risk model with enhanced predictive accuracy. To validate the functional role of signature genes, BMAL1 knockdown in SKBR3 cells disrupted circadian rhythms, with qPCR confirming altered risk gene expression. We found that the nomogram exhibited superior discriminative ability compared to the traditional breast cancer staging system.
Conclusion
We developed a nomogram that can accurately predict the prognosis of breast cancer, and conclude that the expression of CRGs is crucial in breast cancer treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China, ctgu.edu.cn.
- Central Laboratory, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China, ctgu.edu.cn.
- China Three Gorges University, Yichang, Hubei, China, ctgu.edu.cn.
ORCID-Profile: Yanzhen Lu, Lulu Tan, Yuyan Tan
Förderung
- Natural Science Foundation of Hubei Province
Zitieren
APA
Lu, Y., Yang, Y., Yu, D., Tan, Y., Feng, G., Ouyang, L., Tan, L., & Tan, Y. (2025). Deciphering Circadian Rhythm–Related Molecular Subtypes in Breast Cancer and Establishing a Prognostic Prediction Model. BioMed Research International. https://doi.org/10.1155/bmri/9664238
Vancouver
Lu Y, Yang Y, Yu D, Tan Y, Feng G, Ouyang L, et al. Deciphering Circadian Rhythm–Related Molecular Subtypes in Breast Cancer and Establishing a Prognostic Prediction Model. BioMed Research International. 2025. doi:10.1155/bmri/9664238
BibTeX
@article{Lu2025,
author = {Lu, Yanzhen and Yang, Yunfei and Yu, Dan and Tan, Yuxi and Feng, Gang and Ouyang, Liquan and Tan, Lulu and Tan, Yuyan},
title = {Deciphering Circadian Rhythm–Related Molecular Subtypes in Breast Cancer and Establishing a Prognostic Prediction Model},
journal = {BioMed Research International},
year = {2025},
doi = {10.1155/bmri/9664238}
}
EUVIMED